Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://social.coop/users/FreeScholar/statuses/113728453156008138">Micky Metts (freescholar@social.coop)'s status on Saturday, 28-Dec-2024 13:01:19 JST</a><a href="https://social.coop/@FreeScholar" title="freescholar@social.coop"><img src="https://gnusocial.jp/avatar/228019-48-20240101011536.webp" width="48" height="48" alt="Micky Metts" style="position: absolute; left: 0; top: 0;">Micky Metts</a></section><article><p><a href="https://social.coop/tags/luigimangione" rel="tag">#luigimangione</a></p><p>Can we have many more Luigi moments, without death?</p><p><a href="https://eu.usatoday.com/story/money/2016/09/21/mylan-ceo-heather-bresch-epipen-congress-house-testimony/90773250/" rel="nofollow noreferrer">https://eu.usatoday.com/story/money/2016/09/21/mylan-ceo-heather-bresch-epipen-congress-house-testimony/90773250/</a></p><p>Mylan CEO Heather Bresch, the drug dealer that sells the EpiPen allergy-reaction injector defended the company's six-fold price increases in congressional testimony, painting the lifesaving treatment as less profitable than it might appear.</p></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/4268359#notice-8342313">In conversation</a><time datetime="2024-12-28T13:01:19+09:00" title="Saturday, 28-Dec-2024 13:01:19 JST">about a month ago</time> <span>from <span><a href="https://social.coop/@FreeScholar/113728453156008138" rel="external" title="Sent from social.coop via ActivityPub">social.coop</a></span></span><a href="https://social.coop/@FreeScholar/113728453156008138">permalink</a></footer></blockquote>

Corresponding Notice

Embed this notice
Micky Metts (freescholar@social.coop)'s status on Saturday, 28-Dec-2024 13:01:19 JST Micky Metts
#luigimangione
Can we have many more Luigi moments, without death?
https://eu.usatoday.com/story/money/2016/09/21/mylan-ceo-heather-bresch-epipen-congress-house-testimony/90773250/
Mylan CEO Heather Bresch, the drug dealer that sells the EpiPen allergy-reaction injector defended the company's six-fold price increases in congressional testimony, painting the lifesaving treatment as less profitable than it might appear.
In conversationabout a month ago from social.cooppermalink

Public

Embed Notice

HTML Code

Corresponding Notice